[go: up one dir, main page]

CO2020001469A2 - Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak - Google Patents

Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak

Info

Publication number
CO2020001469A2
CO2020001469A2 CONC2020/0001469A CO2020001469A CO2020001469A2 CO 2020001469 A2 CO2020001469 A2 CO 2020001469A2 CO 2020001469 A CO2020001469 A CO 2020001469A CO 2020001469 A2 CO2020001469 A2 CO 2020001469A2
Authority
CO
Colombia
Prior art keywords
inhibitors
compounds
jak kinases
triazole compounds
bicyclic pyrazole
Prior art date
Application number
CONC2020/0001469A
Other languages
English (en)
Inventor
Erik Fenster
Venkat R Thalladi
Jerry Nzerem
Miroslav Rapta
Mandy Loo
Marta Dabros
Robert Murray Mckinnell
Tom M Lam
Anthony Francesco Palermo
Diana Jin Wang
Breena Fraga
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of CO2020001469A2 publication Critical patent/CO2020001469A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona compuestos de la fórmula (I): (I) o una sal farmacéuticamente aceptable de este, donde las variables se definen en la especificación, que son inhibidores de quinasas JAK, particularmente JAK3. La invención también proporciona formas cristalinas, composiciones farmacéuticas que comprenden tales compuestos, métodos para usar dichos compuestos para tratar enfermedades inflamatorias de tipo gastrointestinales y de otro tipo, y procesos y productos intermedios útiles para preparar tales compuestos.
CONC2020/0001469A 2017-08-01 2020-02-11 Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak CO2020001469A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762539642P 2017-08-01 2017-08-01
PCT/US2018/044508 WO2019027960A1 (en) 2017-08-01 2018-07-31 BICYCLIC PYRAZOLO AND TRIAZOLO COMPOUNDS AS JAK KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
CO2020001469A2 true CO2020001469A2 (es) 2020-05-29

Family

ID=63209687

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0001469A CO2020001469A2 (es) 2017-08-01 2020-02-11 Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak

Country Status (23)

Country Link
US (4) US10392368B2 (es)
EP (1) EP3652169A1 (es)
JP (2) JP7098716B2 (es)
KR (1) KR20200036004A (es)
CN (1) CN111032646B (es)
AR (1) AR112348A1 (es)
AU (1) AU2018312349A1 (es)
BR (1) BR112020002265A2 (es)
CA (1) CA3069990A1 (es)
CL (1) CL2020000283A1 (es)
CO (1) CO2020001469A2 (es)
EA (1) EA038912B1 (es)
IL (1) IL272031A (es)
MA (1) MA49570A (es)
MX (1) MX2020001170A (es)
MY (1) MY200629A (es)
PE (1) PE20201028A1 (es)
PH (1) PH12020500201A1 (es)
SG (1) SG11202000602YA (es)
TW (1) TW201920150A (es)
UA (1) UA125318C2 (es)
WO (1) WO2019027960A1 (es)
ZA (1) ZA202000561B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200036004A (ko) 2017-08-01 2020-04-06 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나아제 억제제로서 피라졸로 및 트리아졸로 비시클릭 화합물
EP3914348A1 (en) 2019-01-23 2021-12-01 Theravance Biopharma R&D IP, LLC Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
WO2021009664A1 (en) * 2019-07-15 2021-01-21 Novartis Ag Methods for treating meibomian gland dysfunction with liver x receptor agonists
CA3179566A1 (en) * 2020-04-08 2021-10-14 Pfizer Inc. Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
CN115867272A (zh) 2020-05-14 2023-03-28 施万生物制药研发Ip有限责任公司 肠道选择性jak3抑制剂的给药
CN114075221B (zh) * 2020-08-13 2024-08-23 广东东阳光药业股份有限公司 取代的杂芳基化合物及其组合物和用途
CN114075220A (zh) * 2020-08-13 2022-02-22 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN116157388A (zh) * 2020-09-10 2023-05-23 四川海思科制药有限公司 一种碳环酰胺衍生物及其在医药上的应用
WO2022199599A1 (zh) * 2021-03-23 2022-09-29 凯复(苏州)生物医药有限公司 丙烯酰基取代的化合物、包含其的药物组合物及其用途
KR20230163469A (ko) * 2021-03-29 2023-11-30 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의 결정 형태
CN113061137B (zh) * 2021-04-02 2022-08-02 广西医科大学 含氮杂环衍生物或其药学上可接受的盐和用途
AU2022270072A1 (en) * 2021-05-03 2023-11-02 Incyte Corporation Jak1 pathway inhibitors for the treatment of prurigo nodularis
US20250051360A1 (en) * 2021-12-23 2025-02-13 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compound, and composition and use thereof
WO2023165562A1 (zh) * 2022-03-02 2023-09-07 南京明德新药研发有限公司 含氮杂环类化合物及其应用
GB202213163D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158448A0 (en) 2001-04-20 2004-05-12 Wyeth Corp Heterocyclylalkoxy- alkylthio-and-alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
WO2004113304A1 (en) 2003-05-22 2004-12-29 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
EP1647549A1 (en) 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
EP1959926A1 (en) 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
EP1999135A2 (en) 2006-03-30 2008-12-10 Takeda San Diego, Inc. Kinase inhibitors
KR100834758B1 (ko) 2006-07-05 2008-06-05 삼성전자주식회사 컴퓨터 시스템 보안 장치 및 방법
JP2009007342A (ja) 2007-06-01 2009-01-15 Mitsubishi Tanabe Pharma Corp 医薬組成物
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP5508400B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
US8765743B2 (en) 2008-06-05 2014-07-01 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2009147189A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
JP2011529090A (ja) 2008-07-28 2011-12-01 江蘇国華投資有限公司 アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用
TW201111385A (en) 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
FR2951172B1 (fr) 2009-10-13 2014-09-26 Pf Medicament Derives pyrazolopyridines en tant qu'agent anticancereux
US20120238559A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
PT2635299T (pt) 2010-11-02 2019-10-14 Univ Columbia Métodos de tratamento de distúrbios de perda de cabelo
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN102993201A (zh) * 2011-09-14 2013-03-27 赛诺菲 作为激酶抑制剂的6-(4-羟基-苯基)-3-苯乙烯基-1H-吡唑并[3，4-b]吡啶-4-羧酸酰胺衍生物
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20130102601A1 (en) 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2013060636A1 (en) 2011-10-25 2013-05-02 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013085802A1 (en) * 2011-12-06 2013-06-13 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
ES2694681T3 (es) 2012-03-29 2018-12-26 The Trustees Of Columbia University In The City Of New York Métodos para tratar trastornos de pérdida capilar
WO2013167403A1 (en) 2012-05-09 2013-11-14 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
TWI629275B (zh) 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
JP2016113366A (ja) * 2013-03-29 2016-06-23 大鵬薬品工業株式会社 アセトアミド基を有する１，２，４−トリアジン−６−カルボキサミド誘導体
CU24396B1 (es) 2013-12-05 2019-04-04 Pfizer Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo
CA2937111A1 (en) 2014-01-24 2015-07-30 Abbvie Inc. 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use
EP4019518A1 (en) * 2014-02-28 2022-06-29 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
ES2737696T3 (es) 2014-05-14 2020-01-15 Pfizer Pirazolopiridinas y pirazolopirimidinas
US10519160B2 (en) 2014-07-18 2019-12-31 The General Hospital Corporation Imaging agents for neural flux
CA2965741C (en) 2014-11-03 2022-05-17 Iomet Pharma Ltd Pharmaceutical compound
CN105837574B (zh) 2015-02-02 2018-03-02 四川大学 N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途
US10703756B2 (en) 2015-05-01 2020-07-07 Pfizer Inc. Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof
WO2016179605A1 (en) 2015-05-07 2016-11-10 The Trustees Of Columbia University In The City Of New York Methods and compositions for promoting hair growth
EP3371184A1 (en) 2015-11-03 2018-09-12 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
JP7096592B2 (ja) 2016-02-16 2022-07-06 ワシントン・ユニバーシティ Ｊａｋ阻害剤およびこれらの利用
US10961247B2 (en) 2016-06-30 2021-03-30 Daewoong Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivatives as kinase inhibitor
EP3509572A4 (en) 2016-09-08 2020-05-13 Synergistic Therapeutics, LLC TOPICAL FORMULATION FOR HAIR GROWTH
WO2018075937A1 (en) 2016-10-21 2018-04-26 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
US20180117148A1 (en) 2016-10-28 2018-05-03 Andrew J. Holman Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders
KR102032418B1 (ko) * 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
KR20200036004A (ko) 2017-08-01 2020-04-06 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나아제 억제제로서 피라졸로 및 트리아졸로 비시클릭 화합물
US10981906B2 (en) 2017-11-03 2021-04-20 Aclaris Therapeutics, Inc. Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
NZ764644A (en) 2017-12-28 2023-06-30 Daewoong Pharmaceutical Co Ltd Oxy-fluoropiperidine derivative as kinase inhibitor
EP3914348A1 (en) * 2019-01-23 2021-12-01 Theravance Biopharma R&D IP, LLC Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
CN115867272A (zh) * 2020-05-14 2023-03-28 施万生物制药研发Ip有限责任公司 肠道选择性jak3抑制剂的给药

Also Published As

Publication number Publication date
SG11202000602YA (en) 2020-02-27
US20200216423A1 (en) 2020-07-09
PH12020500201A1 (en) 2020-10-12
US10538513B2 (en) 2020-01-21
CL2020000283A1 (es) 2020-06-12
EA038912B1 (ru) 2021-11-09
MA49570A (fr) 2020-05-20
AR112348A1 (es) 2019-10-16
EA202090413A1 (ru) 2020-06-24
JP2020529987A (ja) 2020-10-15
US10968205B2 (en) 2021-04-06
MY200629A (en) 2024-01-06
US20220119369A1 (en) 2022-04-21
JP2021098751A (ja) 2021-07-01
CN111032646B (zh) 2023-01-03
WO2019027960A1 (en) 2019-02-07
US20190315724A1 (en) 2019-10-17
PE20201028A1 (es) 2020-10-05
TW201920150A (zh) 2019-06-01
EP3652169A1 (en) 2020-05-20
IL272031A (en) 2020-03-31
MX2020001170A (es) 2020-03-12
KR20200036004A (ko) 2020-04-06
CA3069990A1 (en) 2019-02-07
ZA202000561B (en) 2022-04-28
US10392368B2 (en) 2019-08-27
UA125318C2 (uk) 2022-02-16
CN111032646A (zh) 2020-04-17
US20190040043A1 (en) 2019-02-07
JP7098716B2 (ja) 2022-07-11
AU2018312349A1 (en) 2020-02-06
BR112020002265A2 (pt) 2020-07-28

Similar Documents

Publication Publication Date Title
CO2020001469A2 (es) Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak
MX2017015211A (es) Compuestos de naftiridina como inhibidores de quinasa jak.
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
MX2019010539A (es) Compuestos de imidazo-piperidina fusionada que contienen una amida heterociclica de 4 miembros como inhibidores de jak.
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
TN2018000043A1 (en) Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
CU20200053A7 (es) Compuesto de pirimidina como inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
CL2018000611A1 (es) Sales de un inhibidor de pim quinasa
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
EA202192822A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы